Ray Dalio: “There Will Be No Privacy…”

The question circulating in biotech investment committees this week is not whether Merck KGaA overpaid for Silence Therapeutics. The question is whether a 130% premium will look cheap in twelve months, given what just happened in Beijing.

The Deal

Silence Therapeutics entered into a definitive agreement with Merck KGaA under which Merck KGaA will acquire Silence in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion. The all-cash consideration represents a 130% premium to Silence’s ADS closing price on October 16, 2026 and an 82% premium to the 30-day volume-weighted average price of $10.99. Shares rose about 125% on October 19, 2026.

The transaction will add Divesiran, a potentially best-in-class, Phase 3-ready siRNA investigational therapy in development for phlebotomy-dependent polycythemia vera, to Merck KGaA’s pipeline. Divesiran reported an 88% responder rate in Phase 2 and reduced mean phlebotomies versus placebo. That is a clinical profile any large pharma would pay to acquire, and Merck KGaA did exactly that.

Why Wall Street Cares

The timing of this deal is not incidental. Three days before the announcement, China’s Ministry of Commerce published a draft revision to its export control catalogue that would stop foreign buyers acquiring proprietary cell and gene therapy, small interfering RNA platforms, and pathogen gain-of-function platforms developed in China. If those platforms cannot be bought in China, a Western buyer that wants to own one has to look elsewhere, and European-owned platforms in those modalities become scarcer and easier to sell.

That scarcity argument is structural, not cyclical. Large pharma has spent years accessing RNA innovation through Chinese partnerships and licensing. The draft says the restrictions would not reach licensing, partnerships, or outsourced contract research and manufacturing involving these technologies. Licensing remains open; ownership does not. For a buyer who wants to control a platform outright, the Western supply just shrank.

The Bull Case

For investors who believe biotech M&A has genuinely restarted, Merck KGaA’s move is corroborating evidence. The deal was not a distressed acquisition. It follows a competitive sale process, according to the companies. That detail matters: competitive processes mean multiple parties were willing to bid above market. One paid. Others did not.

The siRNA field has generated some of the largest licensing transactions in pharmaceutical history, including Arrowhead’s October 2018 Janssen agreement that was worth up to $3.7 billion. Full platform acquisitions, now constrained in China, represent the next logical step for large pharma seeking durable RNA capabilities.

The Bear Case

The counter-argument is that Silence was a specific asset story, not a sector re-rating. Divesiran’s Phase 2 data were genuinely strong, and Merck KGaA needed a late-stage hematology candidate. The premium reflects that scarcity as much as any macro shift in RNA deal appetite.

Alnylam’s recent trajectory complicates the bull case further. BioPharma Dive reported on July 30, 2026 that Alnylam lost nearly 30% of its market value, close to $12 billion, after surprising investors by lowering financial forecasts for its most important drug franchise by $200 million. Platform leadership does not guarantee commercial execution, and any acquirer pricing a Western RNA business at a steep premium inherits that execution risk.

What Investors Are Missing

The less-discussed consequence of Beijing’s draft rule is the compression it creates among Western RNA platforms still trading at clinical-stage discounts. The consultation runs until November 15, 2026. If it moves toward codification, buyers will begin underwriting scarcity before the ink dries. That front-running could matter more than the Silence deal itself.

Stocks to Watch

Alnylam Pharmaceuticals (ALNY) remains the largest independent RNA platform in public markets. The July guidance cut brought the stock down sharply, which means any acquirer revisiting the name gets a depressed entry point.

Arrowhead Pharmaceuticals (ARWR) is a commercial-stage company, and REDEMPLO (plozasiran) was approved by the FDA in 2025. That pipeline breadth is precisely what an acquirer paying a platform premium would want.

Silence Therapeutics (SLN) is now a deal-spread trade. The transaction is expected to close in the first quarter of 2027, subject to shareholder approval, court sanction, and customary regulatory conditions. The spread is the remaining question, not the direction.